ReShape Lifesciences Inc（RSLS）財務資料RSLSReShape Lifesciences Inc

ReShape Lifesciences Inc (RSLS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is United States, accounting for 83.2% of total sales, equivalent to $1.62M. Other significant revenue streams include Europe and Australia. Understanding this composition is critical for investors evaluating how RSLS navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, ReShape Lifesciences Inc maintains a gross margin of 48.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -165.14%, while the net margin is -211.76%. These profitability ratios, combined with a Return on Equity (ROE) of -101.49%, provide a clear picture of how effectively RSLS converts its operational activities into shareholder value.

In the context of the broader market, RSLS competes directly with industry leaders such as LFWD and DHAI. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, RSLS's gross margin of 48.23% stands against LFWD's 40.90% and DHAI's 47.17%. Such benchmarking helps identify whether ReShape Lifesciences Inc is trading at a premium or discount relative to its financial performance.